American Action Forum Weighs In on 2026 Health Policy Interest Areas

With drug pricing initiatives pacing the way, American Action Forum (AAF) offers a post today reviewing key changes to the pharmaceutical pricing landscape for the coming year. Director of Health Care Policy Michael Baker outlines expectations in four key developing areas, including negotiated pricing for Part D drugs, evolving Center for Medicare and Medicaid Innovation (CMMI) priorities, Pharmacy benefit manager (PBM) reform expectations, and expedited Food and Drug Administration (FDA) decisions. Check his post out here…

Notice: The link provided above connects readers to the full content of the posted article. The URL (internet address) for this link is valid on the posted date; medicarereport.org cannot guarantee the duration of the link’s validity. Also, the opinions expressed in these postings are the viewpoints of the original source and are not explicitly endorsed by AMAC, Inc.; the AMAC Foundation, Inc.; or medicarereport.org.